Filter:   PRESS RELEASES    IN THE NEWS    EVENTS

Sentien Reports on Data from First Ph I/II Study of SBI-101 in Subjects with AKI in STEM CELLS Translational Medicine

Filter:   PRESS RELEASES    IN THE NEWS    EVENTS

Sentien Reports on Data from First Ph I/II Study of SBI-101 in Subjects with AKI in STEM CELLS Translational Medicine

Scientists are reporting promising results in the early stages of a clinical trial designed to gauge the feasibility of a new type of treatment for people with acute kidney disease. Released in STEM CELLS Translational Medicine, the study shows how mesenchymal stromal cells (MSCs) delivered using a new ex vivo drug delivery system – SBI-101 – can keep MSCs viable longer and reprogram the peripheral immune response toward organ repair.

READ PRESS RELEASE >

Sentien Biotechnologies Receives Award from Maryland Stem Cell Research Fund to Support Clinical Study of SBI-101

Filter:   PRESS RELEASES    IN THE NEWS    EVENTS

Sentien Receives Award From Maryland Stem Cell Research Fund to Support Clinical Study of SBI-101 for the Treatment of Acute Kidney Injury Associated with Sepsis

Award to help fund Sentien’s Ph 1/2 clinical study at Maryland sites!

READ PRESS RELEASE >

By
In News
Posted

Sentien to Present SBI-101 Clinical Data in AKI at 2020 ASGCT Annual Meeting that Supports Expansion to COVID-19

Filter:   PRESS RELEASES    IN THE NEWS    EVENTS

Sentien to Present SBI-101 Clinical Data in AKI at 2020 American Society of Gene & Cell Therapy Annual Meeting that Supports Expansion to COVID-19

Sentien’s R&D team will present platform development and clinical data at the American Society of Gene & Cell Therapy Annual Meeting during virtual poster sessions.

Sentien’s SBI-101 clinical data in AKI patients shows immunomodulatory effects consistent with our therapeutic hypothesis and also applicable to COVID-19 patients.

Clinical Evidence for Immune Reprogramming with Extracorporeal Mesenchymal Stromal Cell Therapy

Ex-Vivo Cell Therapy Platform for Immune Reprogramming in Autoimmunity

Sentien Co-Founder Dr. Biju Parekkadan Gives a Live Interview at World Advanced Therapies & Regenerative Medicine Congress

Filter:   PRESS RELEASES    IN THE NEWS    EVENTS

Sentien Co-Founder Dr. Biju Parekkadan Gives a Live Interview at World Advanced Therapies & Regenerative Medicine Congress

Watch Dr. Parekkadan’s interview at the World Advanced Therapies & Regenerative Medicine Congress in London here!
SEE VIDEO >

Cell Trials Data Selects Sentien’s Ph 1/2 Study of SBI-101 for AKI as Its Featured Advanced Cell Therapy Trial

Filter:   PRESS RELEASES    IN THE NEWS    EVENTS

Cell Trials Data Selects Sentien’s Ph 1/2 Study of SBI-101 for AKI as Its Featured Advanced Cell Therapy Trial

In September, our clinical trial was selected by Cell Trials Data as its Featured Advanced Cell Therapy Trial.
READ MORE >

Sentien Announces Open Enrollment in Phase 1/2 Trial of SBI-101 for Patients with Acute Kidney Injury

Filter:   PRESS RELEASES    IN THE NEWS    EVENTS

Sentien Announces Open Enrollment in Phase 1/2 Trial of SBI-101 for Patients with Acute Kidney Injury

Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel approaches to cell therapy, announced that it has opened enrollment in its Phase 1/2 trial of SBI-101 for adult patients with acute kidney injury (AKI). This trial is Sentien’s first clinical program.
READ MORE >

Load More